A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia
Active, not recruiting · Phase 2 · NCT06637501
Conditions: Chronic Lymphocytic Leukemia
At a glance
- Research payments reported, 2025
- $4.4M
- U.S. investigators named
- 14
- Sites paid
- 10
- Planned or actual enrollment
- 94
About the trial
- Sponsor
- BeOne Medicines
- Tested
- Sonrotoclax (drug), Zanubrutinib (drug)
- Dates
- Started 2024-11-14; completion 2029-09
- Results posted
- Not yet
The purpose of this study is to support the registration plan of sonrotoclax plus zanubrutinib treatment in participants with previously untreated chronic lymphocytic leukemia (CLL). This study is designed to assess the contribution of sonrotoclax to the efficacy outcome of the combination of zanubrutinib and sonrotoclax.
From ClinicalTrials.gov, last updated 2026-07-09. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Beone Medicines USA, Inc. reported $4.4M in research payments for this study in 2025 (81 payments).
Products named: Brukinsa
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Yehuda Galili, M.D. Internal Medicine · Weston, FL
- Dean M. Kirkel, MD Hematology & Oncology · Marietta, GA
- Steven L. Mccune, MD, PHD Hematology & Oncology · Marietta, GA
- Destry Elms, M.D. Hematology & Oncology · Maywood, IL
- Seung J. Lee, M.D. Pain Medicine · Baltimore, MD
- Seung Tae Lee, M.D. Hematology & Oncology · Baltimore, MD
- Christopher R. D'angelo, M.D. Hematology · Omaha, NE
- Stefano Tarantolo, M.D. Hematology & Oncology · Omaha, NE
- Steven W. Papish, M.D. Hematology & Oncology · Morristown, NJ
- Richard M. Zuniga, MD Hematology & Oncology · Babylon, NY
- Jeff P. Sharman, M.D. Medical Oncology · Eugene, OR
- Khoan T. Vu, M.D. Hematology & Oncology · Dallas, TX
- Habte A. Yimer IV, M.D. Hematology & Oncology · Tyler, TX
- Stephan D. Kendall, M.D. Medical Oncology · Salt Lake City, UT
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Florida Cancer Specialist (scri) - Fort Myers $1.3M
- Cleveland Clinic Florida $678,570
- Nebraska Cancer Specialists (satellite Site) $660,240
- Northwest Georgia Oncology Centers - Marietta $556,865
- University of Maryland Medical Center $466,165
- The University of Nebraska Medical Cente R / Cente $424,440
- New York Cancer and Blood Specialists $125,760
- Utah Cancer Specialists $90,866
- University of Nebraska $84,686
- Summit Medical Group, P.a. $19,096
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.